CRC Credit Research Compendium
Menu
日本語English

Issuer Credit Research

Biocon Issuer Flash: Q4 / FY2026 Results

Biocon Issuer Flash: Q4 / FY2026 Results

Report date: 2026-05-14 Event date: 2026-05-07 Event title: Q4 FY2026 Results

1. Flash Conclusion

Biocon Limited (“Biocon”)’s Q4/FY2026 results, released on 2026-05-07, reinforced the current issuer_summary view that the credit is “improving, but conditionally.” In FY26, Biosimilars drove growth and EBITDA, consolidated EBITDA increased 25% year on year on the company-adjusted basis, and gross borrowings declined from Rs 17,755 crore at end-March 2025 to Rs 14,824 crore at end-March 2026.

However, these results alone are not enough to materially raise the credit assessment of Biocon/BBL. FY26 finance charges remained heavy at Rs 990 crore, depreciation and amortisation was Rs 1,957 crore, and reported net profit was limited to Rs 386 crore. The FY26 annual report cash flow statement, debt maturity schedule, and the guarantees, collateral and restrictive covenants for the BBL/BBGP notes have not yet been verified. How EBITDA improvement translates into operating cash flow, FCF, refinancing capacity and legal protection remains an item for the next review.

The change from the current issuer_summary is limited. What has changed is that FY26 confirmed Biosimilars margin improvement and debt reduction for the full year. What has not changed is that Biocon remains a credit in the process of improvement, where US pricing and regulatory risk, manufacturing quality, FCF and the subsidiary debt structure require continued monitoring.

2. What Was Announced

On 2026-05-07, Biocon announced consolidated results for Q4 and FY2026, ended 2026-03-31. Q4FY26 operating revenue was Rs 4,517 crore, EBITDA was Rs 1,073 crore, EBITDA margin was 23%, and net profit before exceptional items was Rs 179 crore. Excluding the one-off generic lenalidomide revenue in Q4FY25, the company stated that operating revenue increased 10% and EBITDA increased 29%.

For FY2026, operating revenue was Rs 16,927 crore, EBITDA was Rs 3,798 crore, EBITDA margin was 22%, net profit before exceptional items was Rs 436 crore, and reported net profit was Rs 386 crore. On a basis adjusted for the one-off generic lenalidomide revenue and the BFI divestment gain in FY25, operating revenue increased 13%, EBITDA increased 25%, and EBITDA margin improved by about 200bp.

By segment, Biosimilars was the most important source of improvement. Q4FY26 Biosimilars revenue was Rs 2,756 crore, EBITDA was Rs 720 crore, and EBITDA margin was 26%. For FY26, revenue was Rs 10,431 crore, up 16% year on year, EBITDA was Rs 2,751 crore, and EBITDA margin was 26%. The company cited growth in advanced markets, key tender wins in emerging markets, the US launches of Bosaya and Aukelso, and Health Canada approvals for Denosumab biosimilars.

Generics reported Q4FY26 revenue of Rs 847 crore and an EBITDA margin of 8%. CRDMO / Syngene reported Q4FY26 revenue of Rs 1,037 crore and an FY26 EBITDA margin of 25%.

On the balance sheet, gross borrowings were Rs 14,824 crore as of 2026-03-31. Consolidated provisional net debt after deducting cash and bank balances was about Rs 11,630 crore, which appears to be roughly around 3x FY26 EBITDA. However, this is a simplified calculation that does not adjust for Syngene’s status as a listed subsidiary or for the legal obligors under the BBL/BBGP notes.

3. Credit Read-Through

The positive aspect of these results is that credit improvement has appeared not only in future plans but also in FY26 operating earnings and the debt balance. Biosimilars is central to consolidated EBITDA and delivered a 26% EBITDA margin in both Q4 and the full year. This supports BBL’s business base.

At the same time, the results also reconfirm credit constraints. The gap between EBITDA and bottom-line profit shows that post-acquisition debt, intangible assets, plant and equipment, and R&D investment remain heavy. EBITDA improvement should not be read directly as an improvement in debt repayment capacity without confirming FCF.

Debt reduction is clearly positive, but its quality still needs to be checked. Although FY26-end gross borrowings declined, current borrowings still stood at Rs 4,078 crore. The maturity breakdown, refinanced/unrefinanced status, debt location including the BBL/BBGP notes, and unused committed lines cannot be sufficiently confirmed from the current materials alone.

By segment, the assessment remains that Biosimilars’ improvement is credit positive, while Generics and Syngene are complementary. Syngene supports earnings diversification, but because it is a listed subsidiary with minority interests, it should not be treated as freely available repayment resources for the parent company or BBL debt.

Management’s statement that the integration phase is moving to “Consolidate” has two sides. If integration synergies progress, they could support EBITDA and FCF from FY27 onward. However, completion of integration should not be equated with a simplification of the legal structure or bondholder protections. The effect on the BBGP secured notes’ guarantors, collateral, restricted group, restricted payments and change of control provisions should be verified separately.

In conclusion, these results support maintaining the credit direction at “gradual improvement” and do not represent a deterioration signal. However, until operating cash flow, FCF and the maturity schedule are confirmed in the FY26 annual report, the sustainability of debt reduction should not be strongly asserted. For investors in the BBL/BBGP notes, the improvement in Biocon’s consolidated numbers and the sufficiency of the legal protections for the individual bonds are separate issues.

4. What To Watch Next

The first item to confirm is the FY2026 annual report. Operating cash flow, FCF, capex, working capital, the maturity schedule, borrowings by currency and legal entity, unused committed lines, and restricted cash should be reviewed.

Second, FY27 quarterly results should be monitored to see whether Biosimilars can maintain revenue growth and an EBITDA margin around 26%. Approvals, launches and supply performance for Denosumab, Aflibercept, Ustekinumab, insulin and GLP-1-related products carry pricing, manufacturing, regulatory and litigation risks.

Third, regulatory and quality issues require continued monitoring. Biocon’s credit quality depends on inspections and approvals by the FDA, EMA, PMDA, Health Canada and other agencies. Inspection classifications, EIRs, the presence or absence of warning letters, and approval delays should be tracked by major facility.

Fourth, the BBL/BBGP notes documentation should be checked. Biocon Limited’s domestic bank facility ratings and the credit of BBL/BBGP’s international secured notes are not the same. Until the guarantors, collateral, restricted group, financial restrictions, restricted payments, change of control and early redemption terms are reviewed, consolidated improvement should not be asserted as an improvement in protection for the individual bonds.

5. Sources

Confirmed Sources

6. Unverified / Pending